UY33481A - Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular - Google Patents

Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular

Info

Publication number
UY33481A
UY33481A UY0001033481A UY33481A UY33481A UY 33481 A UY33481 A UY 33481A UY 0001033481 A UY0001033481 A UY 0001033481A UY 33481 A UY33481 A UY 33481A UY 33481 A UY33481 A UY 33481A
Authority
UY
Uruguay
Prior art keywords
treatment
disorders
diseases
composite
back segment
Prior art date
Application number
UY0001033481A
Other languages
English (en)
Inventor
Romano Carmelo
David P Bingaman
Jesse A May
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY33481A publication Critical patent/UY33481A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se da a conocer la utilización de ciertos compuestos de la urea para el tratamiento de trastornos de la retina asociados a la angiogenesis ocular patológica y/o neovascularización.
UY0001033481A 2010-07-02 2011-07-01 Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular UY33481A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36100310P 2010-07-02 2010-07-02

Publications (1)

Publication Number Publication Date
UY33481A true UY33481A (es) 2011-10-31

Family

ID=44543755

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033481A UY33481A (es) 2010-07-02 2011-07-01 Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular

Country Status (13)

Country Link
US (1) US20120004245A1 (es)
EP (1) EP2588098A1 (es)
JP (1) JP2013530230A (es)
KR (1) KR20130102524A (es)
CN (1) CN102985084A (es)
AR (1) AR082077A1 (es)
AU (1) AU2011271518A1 (es)
BR (1) BR112012033388A2 (es)
CA (1) CA2799587A1 (es)
MX (1) MX2012014487A (es)
TW (1) TW201206929A (es)
UY (1) UY33481A (es)
WO (1) WO2012003141A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
CN104758118B (zh) 2010-10-15 2018-04-06 科尼尔赛德生物医学公司 用于进入眼睛的装置
EP2867227B1 (en) * 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
CN105121429B (zh) * 2012-06-28 2017-12-12 诺华股份有限公司 补体途径调节剂和其用途
WO2014002059A1 (en) * 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
EP2872503B1 (en) * 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN110302004B (zh) 2013-05-03 2023-04-28 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
AU2014278231B2 (en) * 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof
JP2017524419A (ja) 2014-06-20 2017-08-31 クリアサイド バイオメディカル，インコーポレイテッド 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
WO2016094710A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1 -amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
WO2017139375A1 (en) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的***深度的装置和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181468A1 (en) * 2002-03-21 2003-09-25 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20050026944A1 (en) 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20050020619A1 (en) 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006050109A2 (en) 2004-10-29 2006-05-11 Abbott Laboratories Novel kinase inhibitors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20070060887A1 (en) 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector

Also Published As

Publication number Publication date
WO2012003141A1 (en) 2012-01-05
MX2012014487A (es) 2013-02-21
CA2799587A1 (en) 2012-01-05
AR082077A1 (es) 2012-11-07
US20120004245A1 (en) 2012-01-05
TW201206929A (en) 2012-02-16
CN102985084A (zh) 2013-03-20
KR20130102524A (ko) 2013-09-17
AU2011271518A1 (en) 2012-12-13
EP2588098A1 (en) 2013-05-08
BR112012033388A2 (pt) 2016-11-22
JP2013530230A (ja) 2013-07-25

Similar Documents

Publication Publication Date Title
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
BR112014005110A2 (pt) pirimidinas aneladas substituídas e utilização das mesmas
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
CR20150358A (es) Derivados de exendina-4 fucionalizada
BR112014008759A2 (pt) tratamento de doença ocular
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR056852A1 (es) INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
BR112013008452A2 (pt) composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
MY184647A (en) Arylated camphenes, processes for their preparation and uses thereof
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
NZ629621A (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
EP3405159A4 (en) TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION
UY33153A (es) Formulación tópica oftálmica de péptidos
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210707